In a report released today, Michael Ryskin from Bank of America Securities reiterated a Buy rating on Danaher (DHR – Research Report), with a price target of $265.00.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Michael Ryskin has given his Buy rating due to a combination of factors that signal potential growth and resilience for Danaher despite recent challenges. Following discussions with Danaher’s CFO Matt McGrew, there is a growing confidence that the company will identify ways to enhance its performance and exceed its initial 2025 projections. Management has acknowledged the current guide is below expectations, but they are actively seeking opportunities to revise it upwards.
While Danaher faces temporary setbacks such as sudden changes in China’s VBP, foreign exchange issues, and specific challenges in their respiratory and Aldevron segments, these are seen as short-term. Management remains optimistic about the company’s long-term growth trajectory, emphasizing consistent topline and earnings growth. Additionally, Danaher’s low exposure to broader economic risks and its strategic interest in mergers and acquisitions further support the positive outlook and Buy rating.
Based on the recent corporate insider activity of 78 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of DHR in relation to earlier this year.